Hydrophobic interaction chromatography (HIC) is a historical strategy used for the analytical
purification and characterization of proteins. Similarly to what can be done in reversed …

Antibody drug conjugates (ADCs) are an emerging new class of targeted therapeutics for
cancer that use antibodies to deliver cytotoxic drugs to cancer cells. There are two FDA …

Antibody–drug conjugates (ADC) have emerged as potent antitumor drugs that provide
increased efficacy, specificity, and tolerability over chemotherapy for the treatment of cancer …

The biopharmaceutical industry has become increasingly focused on developing biosimilars
as less expensive therapeutic products. As a consequence, the regulatory approval of 2 …

Antibody-drug conjugates exhibit complex pharmacokinetics due to their combination of
macromolecular and small molecule properties. These issues range from systemic …

There is a great demand for the development of novel anticancer drugs, due to the
increasing morbidity and high mortality of cancer. To date, chemotherapy still plays a central …

Antibody–drug conjugates have attracted a great amount of attention as a therapeutic
strategy for diseases where targeting specific tissues and cells are critical components, such …

Antibody-based therapies have garnered considerable success in recent years. This is due
to the availability of strategies to successfully engineer antibodies into humanized forms …

Antibody-drug conjugates (ADCs) have become a widely investigated modality for cancer
therapy, in part due to the clinical findings with ado-trastuzumab emtansine (Kadcyla). Ado …

Abstract Antibody-drug-conjugates (ADCs) manufacturing leads to a mixture of species
which needs to be characterized during development and for further quality control. The …